At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Teclistamab (other), Talquetamab (other)
- How long the study runs
- Study runs about 33 months (dates as stated)
- About the drug or intervention
- Teclistamab — other: No Intervention will be administered during the study. · Talquetamab — other: No Intervention will be administered during the study.
- Patient visit burden
- Not specified by the sponsor
In plain English
This study looks at health outcomes for people with relapsed or refractory multiple myeloma (RRMM) — a blood cancer that has come back or not responded to treatment — who received teclistamab or talquetamab outside of clinical trials, in routine care. It is run by Janssen-Cilag Ltd. and uses real-world records rather than giving new treatment.
Who can take part
- A confirmed diagnosis of multiple myeloma
- Received a first dose of teclistamab on or before 31 December 2022 (REALiTEC cohort 1), between 1 January 2023 and 31 December 2024 (cohort 2), or between 1 January 2025 and 31 December 2025 (cohort 3), regardless of how long treatment lasted
- Received a first dose of talquetamab on or before 31 December 2023 (REALiTAL cohort), regardless of how long treatment lasted
- People who received both teclistamab and talquetamab can be in both cohorts
- Received at least one dose of teclistamab or talquetamab
- Signed an informed consent form, or a consent waiver for patients who have died where local rules allow
Who may not be able to
- Received teclistamab as part of an interventional clinical trial (excluded from REALiTEC cohorts)
- Received talquetamab as part of an interventional clinical trial (excluded from REALiTAL cohort)
- Received teclistamab through a Janssen pre-approval access programme (excluded from REALiTEC cohorts 2 and 3)
What taking part involves
- • This study does not give treatment — it collects information on teclistamab and talquetamab already received outside of clinical trials
- • Not stated — ask the trial team
Time commitment: Not stated — ask the trial team about visits, duration, and what taking part involves.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 900
- Started
- 2023-12-18
- Last checked
- 2026-08
Plain English Summary
What is this study?
- • Testing a new treatment for relapsed/refractory multiple myeloma (rrmm)
- • Clinical study - 900 participants
- • The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with relapsed/refractory multiple myeloma (rrmm)
Where?
- • Birmingham - Queen Elizabeth Hospital
- • London - University College Hospital
- • London - Guys and St Thomas NHS Foundation Trust
- • Wolverhampton - The Royal Wolverhampton Hospitals NHS Trust - New Cross Hosp
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
Treatment history
Treatments you must NOT have had:
- ✗ teclistamab as part of an interventional clinical trial
- ✗ talquetamab as part of an interventional clinical trial
What the study is looking for
- ✓Have a documented diagnosis of multiple myeloma
- ✓Received at least one dose of teclistamab/talquetamab
- ✓Provision of a patient-signed agreement to take part form (ICF), or an ICF waiver for deceased patients as applicable...
Who cannot take part
- ✗To be excluded from REALiTEC cohorts if received teclistamab as part of an interventional clinical trial
- ✗To be excluded from REALiTAL cohort if received talquetamab as part of an interventional clinical trial
- ✗Participants who have received teclistamab as part of a Janssen pre-approval access program are excluded from the...
See the full criteria
Where Is This Study? (4 UK sites)
Queen Elizabeth Hospital
Birmingham B15 2GW, United Kingdom
University College Hospital
London NW1 2PG, United Kingdom
Rajinder Sidhu - Associate Director, Research Governance and Operations
uclh.jro-communications@nhs.net020 3447 9825Guys and St Thomas NHS Foundation Trust
London SE1 9RT, United Kingdom
The Royal Wolverhampton Hospitals NHS Trust - New Cross Hosp
Wolverhampton WV10 0QP, United Kingdom
How to Get in Touch
Study Contact
Sponsor contactCONTACT